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Abstract
Background: The formylpeptide receptor family members FPR and FPRL1, expressed in myeloid
phagocytes, belong to the G-protein coupled seven transmembrane receptor family (GPCRs). They
share a high degree of sequence similarity, particularly in the cytoplasmic domains involved in
intracellular signaling. The established model of cell activation through GPCRs states that the
receptors isomerize from an inactive to an active state upon ligand binding, and this receptor
transformation subsequently activates the signal transducing G-protein. Accordingly, the activation
of human neutrophil FPR and FPRL1 induces identical, pertussis toxin-sensitive functional
responses and a transient increase in intracellular calcium is followed by a secretory response
leading to mobilization of receptors from intracellular stores, as well as a release of reactive oxygen
metabolites.
Results: We report that a cell permeable ten amino acid peptide (PBP10) derived from the
phosphatidylinositol 4,5-bisphosphate (PIP2) binding region of gelsolin (an uncapper of actin
filaments) blocks granule mobilization as well as secretion of oxygen radicals. The inhibitory effect
of PBP10 is, however, receptor specific and affects the FPRL1-, but not the FPR-, induced cellular
response. The transient rise in intracellular calcium induced by the active receptors is not affected
by PBP10, suggesting that the blockage occurs in a parallel, novel signaling pathway used by FPRL1
to induce oxygen radical production and secretion. Also the FPR can activate neutrophils through
a PBP10-sensitive signaling pathway, but this signal is normally blocked by the cytoskeleton.
Conclusions:  This study demonstrates that the two very closely related chemoattractant
receptors, FPR and FPRL1, use distinct signaling pathways in activation of human neutrophils. The
PIP2-binding peptide PBP10 selectively inhibits FPRL1-mediated superoxide production and granule
mobilization. Furthermore, the activity of this novel PBP10 sensitive pathway in neutrophils is
modulated by the actin cytoskeleton network.
Published: 29 December 2004
BMC Cell Biology 2004, 5:50 doi:10.1186/1471-2121-5-50
Received: 05 October 2004
Accepted: 29 December 2004
This article is available from: http://www.biomedcentral.com/1471-2121/5/50
© 2004 Fu et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Cell Biology 2004, 5:50 http://www.biomedcentral.com/1471-2121/5/50
Page 2 of 12
(page number not for citation purposes)
Background
The molecular basis for cellular recognition of signal mol-
ecules is their binding to specific cell surface receptors [1].
Despite large structural differences between the huge
numbers of extracellular ligands, many bind to (and acti-
vate) specific receptors belonging to a large family of per-
tussis toxin-sensitive G-protein linked receptors (GPCRs)
[2]. These receptors possess a high degree of similarity and
although activated by different agonists, they transduce
downstream signals that have many common features [3].
Nevertheless, it is clear that there are also important differ-
ences between receptor-ligand pairs regarding their func-
tional repertoire [4]. The pattern recognition, formyl
peptide receptor (FPR) family, belongs to the larger GPCR
group of chemoattractant receptors [5]. The FPR gene fam-
ily has a complex evolutionary history and the number,
function, and specific cell expression of genes comprising
the family vary considerably between different mamma-
lian species [5,6]. Human neutrophil granulocytes express
two FPR members [7], the FPR and the FPRL1 (the formyl
peptide receptor like 1). FPRL1 was originally defined as
an orphan receptor, cloned from an HL-60 cell cDNA
library by low-stringency hybridization with the FPR
sequence [7]. In the past few years several neutrophil acti-
vating ligands specific for FPRL1 have been identified [8],
but knowledge on the precise functional activities and the
signal transduction pathways utilized by FPRL1 are still
somewhat limited. In contrast to FPRL1, a large number of
studies on FPR induced cell function and signaling have
been performed in neutrophils and in receptor-expressing
transfected cell lines. These studies reveal that FPR signal-
ing shows all the basic characteristic of a GPCR. Binding
of the prototype FPR agonist fMLF to its receptor initiates
a chain of events starting with dissociation of the G-pro-
tein α subunit from its βγ subunit. These subunits directly
or indirectly activate downstream signaling molecules
such as protein kinase C (PKC), mitogen-activated protein
kinase (MAPK), and phosphoinositide 3-kinase (PI3K)
that uses the membrane phosphoinositide phosphatidyli-
nositol 4,5-bisphosphate (PIP2) as substrate [9]. The dis-
sociated subunits of the G-protein also activate the
phosphoinositide-specific phospholipase C (PLC) that
upon cleavage of PIP2 produces the second messengers
responsible for an elevation of intracellular free calcium
[8]. It has been assumed that FPRL1 shares signal trans-
duction features with FPR, since both receptors are sensi-
tive to pertussis toxin and possess a high degree of amino
acid identity in the signaling cytoplasmic domains [7].
Further, the functional responses induced by the FPRL1
specific hexapeptide agonist WKYMVM is in most respects
similar to (or even indistinguishable from) those induced
by the prototype FPR agonist fMLF [10-15]. However, in
this study we have used a membrane permeant polyphos-
phoinositide-binding peptide (PBP10 [16]) derived from
the cytoskeletal protein gelsolin, and we show that with
respect to messengers generated by the these receptors
leading to mobilization of secretory granules and
NADPH-oxidase activation, two totally different signaling
routes are used by FPR and FPRL1, one being sensitive
(the FPRL1 route) the other insensitive (the FRP route) to
the PIP2-binding peptide.
Results
NADPH-oxidase activity induced by fMLF and WKYMVM 
and effects of PBP10
The peptides fMLF and WKYMVM, agonists for FPR and
FPRL1, respectively, both induced a robust oxidative burst
measured as a release of superoxide anions (Fig 1). In
accordance with the known receptor specificity [10,17],
the WKYMVM response was totally inhibited by the
FPRL1 specific antagonist WRWWWW whereas the FPR
specific antagonist (cyclosporine H)was without effect.
The effects were reversed for fMLF-triggered activity, that
is, this response was totally inhibited by cyclosporine H
but not affected by WKWWWW (data not shown). The
time-courses of the responses were very similar, as were
the EC50 values (Fig. 1A,B). Both the FPR and FPRL1 medi-
ated response was inhibited by pertussis toxin (whereas
no reduction in oxidase activity was seen with PMA, a PKC
activator that bypasses the G-protein), showing that a het-
erotrimeric G-protein is involved in the signal transduc-
tion of both receptors (Fig. 1C). These indistinguishable
responses were expected, based on the fact that the two
receptors are very similar in the regions suggested to be of
importance for intracellular signaling.
Despite the indistinguishable activation by FPR and
FPRL1 shown in Fig. 1A–C, functional differences
between these two highly homologous receptors emerge
when they are treated with the membrane permeant
polyphosphoinositide-binding peptide rhodamine-B-
QRLFQVKGRR (PBP10; Fig. 1D) prior to activation. The
neutrophil NADPH-oxidase activity was totally inhibited
by PBP10 when FPRL1 was stimulated by WKYMVM,
whereas there was no effect of the peptide on the fMLF-
induced, FPR-mediated neutrophil response. The IC50
value for the WKYMVM induced response was around
0.05 µM whereas no effect was seen on the fMLF induced
activity even at concentrations up to 10 µM. There was no
effect on WKYMVM or fMLF induced superoxide produc-
tion of rhodamine alone (data not shown).
The neutrophil response is inhibited by Wortmannin
The amino acid sequence of PBP 10 peptide corresponds
to the phosphatidylinositol 4,5-bisphosphate (PIP2)
binding region segment 2 of the cytoskeletal protein gel-
solin [16]. Following G-protein coupled receptor (GPCR)
activation, the dissociated G-protein subunits activate the
downstream phosphoinositide remodeling enzyme phos-
phatidylinositol 3-kinase (PI3K) [18], an enzyme thatBMC Cell Biology 2004, 5:50 http://www.biomedcentral.com/1471-2121/5/50
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uses the membrane phosphoinositide PIP2 as substrate to
generate the signaling molecule phosphatidylinositol
3,4,5-trisphosphate (PIP3) [9]. The oxidase activity
induced by fMLF as well as by WKYMVM was largely
inhibited by the specific PI3K inhibitor Wortmannin (Fig.
2A) suggesting that this signaling pathway is of impor-
tance in the cellular response. In contrast to the effect of
PBP10, the effects of the PI3K inhibitor showed no specif-
icity in the inhibition of the WKYMVM/FPRL1 triggered
response.
PBP 10 inhibits the response to FPRL1 but not to FPR
The inhibition induced by PBP10 on neutrophil oxidase
activity was linked to the receptor FPRL1 rather than to an
FPRL1-specific agonist, since the same inhibition pattern
was obtained when WKYMVM was replaced by serum
Oxidase activity induced by peptide agonists and the effect of PBP 10 Figure 1
Oxidase activity induced by peptide agonists and the effect of PBP 10. Neutrophils were activated by fMLF or 
WKYMVM and the extracellular release of superoxide anions was recorded by chemiluminescence (expressed in Mcpm). (A) 
The figure shows the kinetics of the neutrophil response to two concentrations (100 nM and 20 nM) of fMLF or WKYMVM. 
(B) Dose dependent oxidase activation induced by the two agonists. The peak values were measured and the responses are 
given as percent of the maximal response. (C) Neutrophils were incubated for 120 minutes in the absence (control) or pres-
ence of pertussis toxin (PTX; 500 ng/ml) and the cells were then activated with fMLF (100 nM), WKYMVM (100 nM) or the 
receptor independent PKC activator PMA (100 nM) (inset). For comparision, the response induced by the two peptides after 
90 minutes long incubation time with pertussis toxin is also included. (D) Effect of different concentrations of PBP10 on the 
neutrophil NADPH-oxidase response induced by fMLF or WYMVM, respectively. Data are expressed as percent of control 
(without PBP10; mean ± SD of three independent experiments).
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amyloid A (SAA) (Table 1), an agonist that activates cells
through binding to FPRL1 [19]. Moreover, no effect was
induced by PBP10 when fMLF was replaced by annexinI9–
25 (Table 1), a 17 amino acid peptide derived from the N-
terminus of annexin I that has been shown to be a FPR
agonist ([20] and our own observation). Moreover, the
Effect of different inhibitors on the neutrophil NADPH-oxidase activity Figure 2
Effect of different inhibitors on the neutrophil NADPH-oxidase activity. (A) Neutrophils were incubated with differ-
ent concentrations of the PI3K specific inhibitor Wortmannin at 37°C for 30 minutes followed by stimulation with fMLF (100 
nM) or WKYMVM (100 nM). A representative experiment is shown. (B) Neutrophils were incubated with the cell impermea-
ble PIP2 binding peptide QRLFQVKGRR (1 µM final concentration) at 37°C for 5 minutes followed by stimulation with 
WKYMVM (100 nM). The effect of PBP10 (1 µM) is included for comparison.
Table 1: Effect of PBP10 on neutrophil NADPH-oxidase activity induced by receptor agonists#.
Neutrophil NADPH-oxidase activator 
(Concentration)
Neutrophil  receptor(s) Inhibition of NADPH-oxidase by PBP10 (1 µM)
WKYMVM (100 nM) FPRL1 +
SAA (5 µM) FPRL1 +
fMLF (100 nM) FPR -
Annexin9–25 (50 µM) FPR -
C5a (100 ng/ml) C5aR -
IL-8 (100 ng/ml) CXCR1, CXCR2 -
Abbreviations: C5a, complement 5a; FPR, formyl peptide receptor; IL-8, interleukin 8; SAA, serum amyloid A.
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cellular responses mediated through other receptors, such
as the chemokine receptor CXC or the C5a-receptor were
not affected by PBP10 (Table 1).
The membrane permeability of PBP10 is necessary for 
FPRL1 inhibition
Interaction of PBP10 with PIP2 depends on the peptide
sequence, as truncation of the peptide either at the N ter-
minus or C terminus reduces the PIP2 binding affinity
[21]. Accordingly, Rh-VKGRRG affected the oxidase activ-
ity induced by WKYMVM only when higher concentra-
tions of peptide were used (IC50 = 1 µM compared to 0.05
µM for PBP10) suggesting that PIP2 binding is of impor-
tance for inhibition of the neutrophil oxidase response
induced by FPRL1.
The PBP10 peptide possesses not only PIP2 binding capac-
ity but is also membrane permeable. This feature has been
shown to be coupled to the rhodamine B part of the mol-
ecule, i.e., the unconjugated peptide QRLFQVKGRR
exhibits the same PIP2-binding characteristics as PBP10
but lacks the ability to cross the plasma membrane [16].
The unconjugated peptide had no effect on the WKYMVM
induced neutrophil oxidase activity (Fig. 2B) suggesting
that membrane permeation is required for peptide-
induced inhibition.
No effect of PBP10 on the transient calcium response
PIP2 is utilized for generation of IP3 that induces a tran-
sient increase in intracellular calcium [22], we thus inves-
tigated the effect of PBP10 on the neutrophil calcium
response. Stimulating the cells with fMLF or WKYMVM
induced a rapid and transient increase in cytosolic cal-
cium. These responses were not significantly reduced by
the removal of extracellular Ca2+ with EGTA (data not
shown), suggesting that the rise in intracellular free Ca2+
relates to a mobilization from calcium storing organelles
rather then from an influx through ion channels in the
plasma membrane. Treatment of the cells with PBP10
prior to stimulation did not alter the calcium responses,
neither induced by fMLF nor by WKYMVM (Fig. 3).
Hence, the PBP10-induced effect on FPRL1 signaling is
not due to a specific inhibition of the calcium transients
induced by the activated GPCRs.
PBP10 inhibits mobilization of CR3
The Ca2+ elevation has been claimed to be required but
not sufficient for the generation of an NADPH-oxidase
activating signal from FPR [23,24]. Likewise, the mobili-
zation through regulated exocytosis of neutrophil secre-
tory storage organelles containing reserve pools of cell-
surface receptors [25] has been suggested to be directly
regulated by the cytosolic concentration of free Ca2+
[26,27]. We found that despite the fact that PBP10 was
without effect on the transient rise in intracellular Ca2+
induced by WKYMVM, it blocked the secretory response
(Fig. 4). In accordance with the inhibition of the NADPH-
oxidase activity, PBP10 was without effect on the FPR
induced granule mobilization (Fig. 4). This suggests that
degranulation and NADPH-oxidase activity induced by
FPRL1 both are on the same, PBP10-sensitive, signal
transduction pathway in contrast to FPR, which induces
both cellular functions by a PBP10-insensitive pathway.
Regulation by the cytoskeleton
Regulation of FPR signaling has been suggested to involve
mechanisms that depend on direct receptor interaction
with the membrane cytoskeleton [28]. It is well known
that the neutrophil response to FPR and FPRL1 agonists is
both augmented and prolonged in the presence of cytoch-
alasin B [15], a fungal metabolite that inhibits re-organi-
zation of actin polymers and uncouples receptors from
the cytoskeleton [13].
To investigate the involvement of cytoskeleton in the
PBP10-sensitive signal transduction pathway, neutrophils
were treated with cytochalasin B prior to activation by a
receptor agonist (in the presence or absence of PBP10).
Interestingly, the receptor selectivity of PBP10's inhibitory
effect was lost when the receptors were first uncoupled
from the cytoskeleton by cytochalasin B (Fig. 5). In
accordance with the findings reported above, the NADPH-
oxidase activity induced by WKYMVM was largely inhib-
ited by PBP10 also in the presence of cytochalasin B. How-
ever, the drug introduced a PBP10 sensitivity also in the
FPR-induced response. The inhibition of the FPR-medi-
ated response required higher concentrations of PBP10,
and the response was only partly inhibited suggesting that
the PBP10-insensitive as well as the PBP10-sensitive sign-
aling pathways were triggered simultaneously during acti-
vation of FPR uncoupled from the cytoskeleton. The
transient rise in intracellular calcium induced by the active
receptors was not affected by cytochalasin B (data not
shown). In conclusion, both FPRL1 and FPR appear to
possess the ability to activate neutrophils via a signaling
route that is sensitive to PBP10, but that this signaling
pathway normally is blocked for FPR, through association
of the receptor with the cytoskeleton.
Discussion
The two formyl peptide receptor family members FPR and
FPRL1 possess a high degree of amino acid identity in the
signaling cytoplasmic domains [7], and the cell functions
induced by the FPR and FPRL1 agonists are in most
respects identical [10-15]. The indistinguishable
responses of activated FPR and FPRL1 respectively, are
expected, based on the fact that the two receptors are very
similar in the regions suggested to be of importance for
their interaction with the signaling, pertussis toxin-sensi-
tive heterotrimeric G-protein. Dysfunctional variant FPRBMC Cell Biology 2004, 5:50 http://www.biomedcentral.com/1471-2121/5/50
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alleles (F110 replaced by an S and C126 replaced by a W)
have been described that are associated with juvenile per-
iodontitis and a deficiency in G-protein coupling [29,30],
but FPRL1 contains the functional amino acids of FPR
both in position 110 and in 126. Other G-protein cou-
pling structures, identified through expression of different
FPR mutants, suggest that the N-terminal part of the sec-
ond transmembrane domain (S63 and D71) and the C-
terminal interface of the third transmembrane domain
(R123, C124 and C126) may be sites of interaction
between the receptor and the G-protein [31]. In FPRL1 all
but one of the amino acids in these suggested interaction
sites are identical with those in FPR, and the signal-regu-
lating NPXXY motif in the seven transmembrane domain
(highly conserved among all GPCRs) is identical
(sequence NPMLY [32]) in the two receptors. The excep-
tion is the serine in position 63 that in FPRL1 is replaced
by a cysteine, but this difference seems to be of minor
importance with respect to the effect of pertussis toxin,
since both receptors are sensitive to the toxin.
Effect of PBP10 on cytosolic calcium mobilization induced by peptide agonists Figure 3
Effect of PBP10 on cytosolic calcium mobilization induced by peptide agonists. Neutrophil intracellular calcium 
mobilization was analyzed by monitoring Fura-2 fluorescence upon stimulation with the FPR agonist fMLF (100 nM; left) or the 
FPRL1 agonist WKYMVM (100 nM; right) in the absence (upper curves) or presence (lower curves) of PBP10 (1 µM). The 
curves are derived from a representative experiment. The calcium concentrations given in the right hand part of the figure are 
valid for the fMLF as well as the WKYMVM induced responses.
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Despite the indistinguishable activation by FPR and
FPRL1, functional differences between these two highly
homologous receptors emerge when they are challenged
by the membrane permeant polyphosphoinositide-bind-
ing peptide PBP10 (rhodamine B-QRLFQVKGRR) prior to
activation. The FPRL1-mediated neutrophil activity was
totally inhibited by the peptide PBP10 whereas there was
no effect on FPR-mediated responses. As mentioned, the
amino acids in the PBP 10 peptide correspond to the PIP2
binding region segment 2 of the cytoskeletal protein gel-
solin [16]. One of the enzymes competing with PBP10 for
PIP2 would be the phosphoinositide remodeling enzyme
PI3K that converts PIP2 into phosphatidylinositol 3,4,5-
trisphosphate (PIP3) which is of importance for cell loco-
motion and the associated dynamic reorganization of
cytoskeletal components. The precise target for PIP3 has
however not yet been defined [33]. The inhibition of neu-
trophil function by Wortmannin, an inhibitor of PI3K,
suggests that this signaling pathway is of importance for
the NADPH-oxidase activity but the PI3K inhibitor lacked
receptor specificity (i.e., both FPR and FPRL1 induced
responses were inhibited) and we can thus rule out that
Effect of PBP10 on fMLF and WKYMVM induced mobilization of CR3 to the neutrophil cell surface Figure 4
Effect of PBP10 on fMLF and WKYMVM induced mobilization of CR3 to the neutrophil cell surface. Neutrophils 
were incubated with or without PBP10 (1 µM) at 37°C for 5 minutes after which the cells were challenged with fMLF (100 nM) 
or WKYMVM (100 nM) for another 10 minutes. After fixation of the cells with paraformaldehyde and labeling with anti-CR3 
antibody, the amount of CR3 on the cell surface was determined by FACS analysis. A representative histogram of PBP10 effect 
on WKYMVM mediated CR3 exposure is shown (inset), and the exposure of CR3 after cell stimulation with fMLF and 
WKYMVM is expressed as percent of control (without PBP10; mean ± SD of four independent experiments). *p < 0.05 com-
pared to WKYMVM without PBP10.
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the mechanism behind the PBP10 effect is a direct inter-
ference with the PI3K pathway.
The basic properties of PBP 10 have been described earlier
[16,21,34], and it has been shown that when coupled to
rhodamine B the peptide possesses not only PIP2 binding
activity but also crosses the cell membrane of neutrophils
and other cells. Interaction of rhodamine labeled peptides
with PIP2 depends on the peptide sequence, and trunca-
tion of the peptide reduces the PIP2 binding affinity [21].
The truncated peptides were still membrane permeable
and affected the oxidase activity only at higher concentra-
tions. The unconjugated peptide QRLFQVKGRR exhibit-
ing the same PIP2-binding characteristics as PBP10 but
lacking the ability to cross the plasma membrane [16] had
no effect on neutrophil oxidase activity. Taken together
these data suggest that membrane permeation is required
and PIP2 binding is of importance for peptide-induced
inhibition.
Plasma membrane localized PIP2 is utilized for generation
of IP3 which in turn is responsible for inducing transients
in intracellular calcium [22]. Triggering of cells with fMLF
or WKYMVM induced a rapid and transient increase in
cytosolic calcium, but PBP10 did not have any inhibitory
effect on the calcium transient. The Ca2+ elevation has
been claimed to be required but not sufficient for the gen-
eration of an NADPH-oxidase activating signal from FPR
[23,24]. Likewise the mobilization of granule localized
reserve pools of cell-surface receptors [25], has been sug-
gested to be directly regulated by the cytosolic concentra-
tion of free Ca2+ [26,27]. These experimental evidences
rely, however, on methods that cannot distinguish a
dependency on basal Ca2+ levels from a requirement for a
Ca2+ transient, and we have earlier shown that receptor
mobilization can occur and the oxidase can be activated
without any transient rise in cytosolic Ca2+ [13,35,36].
Despite the fact that PBP10 was without effect on the
transient rise in intracellular Ca2+ induced by WKYMVM,
Effect of PBP10 on oxidase activity induced by peptide agonists in the presence of cytochalasin B Figure 5
Effect of PBP10 on oxidase activity induced by peptide agonists in the presence of cytochalasin B. Neutrophils 
were activated by fMLF (100 nM) or WKYMVM (100 nM) in the presence of cytochalasin B (2.5 µg/ml, final concentration) and 
the extracellular release of superoxide anion was recorded (expressed in Mcpm). (A) The figure shows the kinetics of the neu-
trophil response to fMLF in the absence (solid line) and presence (broken line) of PBP10 (5 µM). The results obtained are sum-
marized in the inset, expressed as the integral values of oxidase activities from the controls (presence of cytochalasin B but not 
PBP10) and the activities in the presence of both cytocalasin B and PBP10. (B) The figure shows the kinetics of the neutrophil 
response to WKYMVM in the absence (solid line) and presence of PBP10 (broken line). The results obtained are summarized 
in the inset and expressed as the integral values of oxidase activities from the controls (presence of cytochalasin B but not 
PBP10) and the activities in the presence of both cytochalasin B and PBP10.
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the secretory response was blocked and PBP10 selectively
inhibited the FPRL1 induced granule mobilization.
The GPCR family is very diverse and the transmission of
signals by such receptors is a critical function in many cell/
organ systems. Signaling through GPCRs is highly com-
plex, evidently not only with respect to the wide variety of
mechanisms that regulate different functional responses
[2], but also with respect to the pathways used to regulate
a defined cellular response through closely related
receptors. The two FPR and FPRL1 genes, although origi-
nating from a common ancestral gene, appear to have
undergone markedly different evolutionary events [37].
In contrast to FPR, which is characterized by a relatively
high degree of single nucleotide polymorphism (five non-
synonymous and two synonymous identified [37]), no
FPRL1 polymorphism has been found. Only one of the
FPR polymorphisms is located in the cytoplasmic regions;
and the variant (containing the A346 → E exchange) has
the same amino acid in that position in the cytoplasmic
tail as FPRL1. A direct comparison of the amino acid
sequences of FPR and FPRL1 reveal very small differences
between the receptors in all intracellular domains except
for the C-terminal tail. In the first intracellular loop the
H57 in FPR is replaced by an R (H57 → R) in FPRL1, in
the second loop differences are found in V125 → I and
T133 → A, and in the third loop the Q231 → K and L233
→ M exchanges are found. The only major differences
between the two receptors are found in the cytoplasmic C-
terminal tail in which 13 out of 45 amino acids differ, and
it is worth noting that the amino acid exchange in nine of
the positions that differ between FPR and FPRL1 are
potential targets for phosphorylation. Five potential phos-
phorylation sites, suggested to be of importance for arres-
tin-binding and receptor desensitization in FPR [38], are
missing in FPRL1 while two new sites have been added in
this receptor. It seems reasonable to assume that the sign-
aling route that is sensitive to PBP10 originates from this
region of the FPRL1 receptor. Despite the fact that the dif-
ferences between FPR and FPRL1 are limited, the identifi-
cation of putative sites in FPRL1 of importance for the
PBP10 sensitivity cannot be achieved through experi-
ments performed with receptor chimeras, site-directed
receptor mutants or deletions, since no cells equipped
with the required effector functions are available for
expression of the receptors.
Regulation of FPR signaling has been suggested to involve
mechanisms that depend on direct receptor interaction
with the membrane cytoskeleton [28]. It is well known
that the neutrophil response to FPR and FPRL1 agonists is
both augmented and prolonged in the presence of cytoch-
alasin B [15], a drug that inhibits re-organization of actin
polymers and uncouples the receptors from the cytoskele-
ton [13,36]. The cytoskeleton is part of the signaling mod-
ulating machinery and we show that the receptor
selectivity of the PBP10 inhibitory effect was lost when the
receptors were uncoupled from the cytoskeleton. In
accordance with the earlier described findings, the
NADPH-oxidase activity induced by WKYMVM was
largely inhibited by PBP10 also in the presence of cytoch-
alasin B, but the drug introduced this sensitivity when
fMLF was used as the triggering agent. The inhibition of
the FPR-mediated response required higher concentra-
tions of PBP10, and the response was only partly inhib-
ited suggesting that the PBP10-insensitive as well as
PBP10-sensitive signaling pathways were activated simul-
taneously by FPR's uncoupled from the cytoskeleton. It is
interesting to note that when FPR was uncoupled from the
cytoskeleton by cytochalasin B, PBP10 affected the sus-
tained generation of superoxide but not the initial rate of
production. This suggests that different signals are respon-
sible for the triggering of the oxidase in the early and late
phases of the response, respectively. It is reasonable to
assume that the PBP10 sensitive signal generated by the
uncoupled FPR is identical to that generated by FPRL1,
however, we cannot at present exclude the possibility that
also a novel FPR-triggered pathway is blocked by PBP10.
The transient rise in intracellular calcium induced by the
active receptors was not affected by cytochalasin B (data
not shown), suggesting that this signaling route does not
depend on interaction with the cytoskeleton. A possible
explanation for the effects when PBP10 and cytochalasin
B are combined is that signaling G-proteins compete with
cytoskeletal proteins for the same site on FPR, and that
this interaction involves a region of the receptor that
differs between FPR and FPRL1. A 15 amino acid long
sequence in FPR (322FPR336) has a fairly high (45–50%)
identity with the actin-binding cytoskeletal proteins vin-
culin and coronin, and this region also participates in FPR
interaction with the G-protein [28]. It is of interest to
notice that the amino acid sequence in this region of
FPRL1 differs from that of FPR in five positions and four
of these are (in FPR) potential phosphorylation sites.
Phagocytes express predominantly the Giα2 complex of
the pertussis toxin sensitive G-proteins and, to a lesser
extent Giα3 [39]. The molecular mechanism behind the
difference in sensitivity to PBP10 between FPR and FPRL1
could possibly be that the receptors couple to different G-
protein subtypes. FPR has, however, been shown to cou-
ple to both G-protein subtypes with similar efficiency
[40]. It is however important to note that these experi-
ments were performed in receptor-expressing cells in
which nothing is known about the linkage between the
receptors and the cytoskeleton and in which the proper
cell function repertoire is missing.
The relation of the biochemical/biophysical activities of
the PBP10 peptide to its effect on the FPRL1-triggered cell
function is not obvious and is likely to be complex. TheBMC Cell Biology 2004, 5:50 http://www.biomedcentral.com/1471-2121/5/50
Page 10 of 12
(page number not for citation purposes)
sensitivity to PBP10 seems to be unique to FPRL1, but this
receptor is expressed also in other cells such as astrocytes,
neuroblastoma, and microglia cells [8]. FPR is also
expressed in other cell types and whether the receptor
selectivity/specificity of PBP10 is maintained in other cells
remains to be determined. The biochemical/biophysical
characterization of the ten strategically organized basic
and hydrophobic amino acids of the gelsolin molecule
included in PBP10 reveal that it may interact with a broad
range of negatively charged phosphomonoesters and
hydrophobic acyl chains of anionic phospholipids
[41,42]. This suggests that in addition to blocking/com-
peting activities which involve proteins that are regulated
by cellular phosphoinositides, the peptide may function
as a buffer of bioactive and signaling lipids. Although elu-
cidation of the step in signal transduction that is disrupted
by PBP10 requires much additional work, the receptor-
specific and signal-selective effects of this peptide on neu-
trophil functions suggest that it has a potential as a tool to
manipulate and help define how GPCRs produce and
integrate the signals generated from activated receptors
and to probe new signaling functions of polyphosphoi-
nositides as well as defining the role as promotor/blocker
of G-protein signaling of different cytoskeletal proteins.
Conclusions
The neutrophil formyl peptide receptor family members
FPR and FPRL1 share 69% of amino acid identity and
mediate almost indistinguishable cellular responses.
Thus, the assumption that FPR and FPRL1 use the same
signaling pathways has been generally accepted. However,
in this study we clearly demonstrate a fundamental differ-
ence in intracellular signaling between these two very
closely related neutrophil formyl peptide receptor mem-
bers, one being PBP10 sensitive and the other not. This
novel PBP10 sensitive signaling pathway utilized by
FPRL1 is also used by FPR but only when the cytoskeleton
network is disrupted.
Methods
Isolation of human neutrophils
Neutrophil granulocytes were isolated from buffy coats
obtained from healthy adults. After dextran sedimenta-
tion at 1 × g, hypotonic lysis of the remaining erythro-
cytes, and centrifugation in a Ficoll-Paque gradient [43],
the neutrophils were washed twice and resuspended (1 ×
107 /ml) in Krebs-Ringer phosphate buffer containing glu-
cose (10 mM), Ca2+ (1 mM), and Mg2+ (1.5 mM) (KRG;
pH 7.3). The cells were stored on melting ice and used
within 120 min of preparation.
Chemoattractants and stimuli
The hexapeptide Trp-Lys-Tyr-Met-Val-Met-NH2
(WKYMVM) and the annexin I peptide (annexin9–25 Ac-
QAWFIENEEQEYVQTVK) were synthesized and HPLC-
purified by Alta Bioscience (University of Birmingham,
Birmingham, United Kingdom), and Ross-Petersen ApS
(Holte, Denmark). The formylated peptide N-formyl-Met-
Leu-Phe (fMLF), C5a, and, phorbol myristate acetate
(PMA) were from Sigma Chemical Co. (St. Louis, Mis-
souri). IL-8 was from R&D systems (Minneapolis, MN)
and dissolved in KRG containing 0.5% (w/v) bovine
serum albumin. Serum amyloid A (SAA) was from Pepro
Tech Inc. (UK). The C5a and SAA were dissolved in water
while the other peptide agonists were dissolved in dime-
thyl sulfoxide to 10-2 M and stored at -70°C until use. Fur-
ther dilutions were made in KRG.
PBP10 synthesis
The peptide QRLFQVKGRR (gelsolin residues 160–169)
and related peptides were prepared by solid phase peptide
synthesis and coupled to rhodamine as described earlier
[16].
Neutrophil NADPH-oxidase activity
Neutrophil production and release of superoxide anions
was measured by means of an isoluminol-enhanced
chemiluminescence (CL) assay [44]. The CL activity was
measured in a six-channel Biolumat LB 9505 apparatus
(Berthold Co., Wildbad, Germany), using disposable 4-
ml polypropylene tubes with a 900-µl reaction mixture
containing 105–106 neutrophils, horseradish peroxidase
(4 U) and isoluminol (20 µM) with and without cytocha-
lasin B or PBP10. The measuring tubes were equilibrated
for 5 to 10 minutes at 37°C and the cells were activated by
addition of a receptor specific peptide agonist, fMLF for
FPR and WKYMVM for FPRL1. The light emission was
recorded continuously. Details about the CL technique
are given in [45].
Determination of changes in cytosolic calcium
Neutrophils at a density of 2 × 107/ml in Ca2+-free KRG
supplemented with bovine serum albumin (BSA, 0.1%)
were incubated with the acetoxymethylated derivative
fura-2/AM (2 µM) at room temperature for 30 minutes.
The cells were washed twice and resuspended in KRG,
adjusted to 2 × 107/ml and kept protected from light on
ice until use. Cells with or without PBP10 were equili-
brated for 5 minutes at 37°C, after which the peptide ago-
nist was added. The fura-2 fluorescence was followed with
a luminescence spectrometer (LS50B; Perkin Elmer Corp.)
using excitation wavelengths of 340 nm and 380 nm, and
an emission wavelength of 510 nm and the [Ca2+]i was
calculated as described earlier [46].
Determination of receptor exposure by FACS analysis
The exposure of CR3 (CD11b/CD18) on the neutrophil
cell surface was assessed by immunostaining and FACS-
analysis. Cells challenged with peptide agonists with or
without PBP10 were fixed with ice-coldBMC Cell Biology 2004, 5:50 http://www.biomedcentral.com/1471-2121/5/50
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paraformaldehyde and washed with FACSwash (PBS,
0.02% NaN3), after which the cells were incubated at 4°C
with phycoerythrin-conjugated anti-CR3 antibodies
(CD11b; Becton Dickinson 10 µl/106 cells) before analy-
sis using a FACScan (Becton Dickinson, Mountain View,
CA).
Reagents
Horseradish peroxidase (HRP) was from Boehringer-Man-
nheim (Mannheim, Germany). Isoluminol, cytochalasin
B, and pertussis toxin were purchased from Sigma. Dex-
tran and Ficoll-Paque were from Pharmacia (Uppsala,
Sweden), and Wortmannin was from Calbiochem (La
Jolla, CA). Fura-2AM was from Molecular Probes Inc.
(Eugene, OR).
Statistic analysis
Two-tailed, paired Students's t-tests were performed to
determine statistical significance, and a P-value of < 0.05
was regarded as significant.
Abbreviations
GPCR – G-protein coupled receptor
PBP – Phosphoinositide binding peptide
FPR – formyl peptide receptor
FPRL1 – formyl peptide receptor-like 1
PIP2 – phosphatidylinositol 4,5-bisphosphate
PI3K – phosphatidylinositol 3-kinase
fMLF – formyl-methionly-leucyl-phenylalanin
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